Straits Times Index
3,330.81 +0.80 (+0.02%) S&P 500
5,355.10 +1.07 (+0.02%) Dow
38,820.54 +13.21 (+0.03%) Nasdaq
17,196.23 +8.33 (+0.05%) Bitcoin USD
71,297.73 +448.71 (+0.63%) CMC Crypto 200
1,521.09 -3.71 (-0.24%)
MYGN Nov 2024 26.000 call
| Previous close | 2.4700 |
| Open | 2.4700 |
| Bid | 2.0500 |
| Ask | 2.6500 |
| Strike | 26.00 |
| Expiry date | 2024-11-15 |
| Day's range | 2.4700 - 2.4700 |
| Contract range | N/A |
| Volume | |
| Open interest | 22 |
GuruFocus.comInsider Sale: Director Daniel Spiegelman Sells Shares of Myriad Genetics Inc (MYGN)
On June 4, 2024, Daniel Spiegelman, Director at Myriad Genetics Inc (NASDAQ:MYGN), executed a sale of 7,576 shares of the company.
GlobeNewswireMyriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
SALT LAKE CITY, June 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of a new Universal Plus Panel to its Foresight® Carrier Screen. The panel includes 39 conditions and screens up to 272 genes associated with serious inherited conditions. The conditions added to the Universal Plus panel were named in the American College of Medical Genetics and Genomics (ACMG) practice resource for carrier screen
- GlobeNewswire
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics (ACMG), published a new study validating RiskScore®, Myriad’s breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test. RiskScore combines a polygenic risk score (PRS) validated for all ancestries with the Tyre
